Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Clinical trial NCT07591831 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07591831
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-30
- Primary completion
- 2027-05-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.